Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
jyseleca save search
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.06%
H: 1.12%
C: -0.42%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.24%
H: 1.33%
C: 1.2%
jyseleca transfer business
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
Published: 2024-01-02 (Crawled : 06:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.12%
H: 3.52%
C: 2.88%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.12%
H: 2.22%
C: 1.82%
jyseleca transfer business agreement
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Published: 2023-10-30 (Crawled : 20:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 1.44%
C: 1.22%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.27%
H: 2.29%
C: 2.04%
jyseleca transfer business
Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting
Published: 2023-04-19 (Crawled : 14:00) - biospace.com/
ATNM | $6.85 2.7% 0.0% 350K
|
Health Technology
|
| O: -0.86%
H: 1.73%
C: -0.54%
tumors tumor meeting potential
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Published: 2022-11-11 (Crawled : 12:20) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.44%
H: 0.7%
C: 0.5%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.55%
H: 1.8%
C: 1.41%
jyseleca chmp review
Jyseleca® approved in Japan for ulcerative colitis
Published: 2022-03-28 (Crawled : 08:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.07%
H: 0.7%
C: 0.39%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.83%
H: 1.42%
C: -1.11%
jyseleca ulcerative colitis
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
jyseleca treatment license ulcerative colitis
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Published: 2021-11-15 (Crawled : 16:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.34%
H: 1.74%
C: -0.4%
treatment europe ulcerative colitis
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
treatment positive chmp ulcerative colitis